Sign In
Buy PASG
$4.47
-0.0200 (-0.445%)
At Close: Jul 31, 2026
Passage Bio Receives MHRA Clinical Trial Authorization for PBGM01 for Treatment of GM1 Gangliosidosis
04:01pm, Thursday, 10'th Dec 2020
- MHRA approval represents first clinical trial authorization for the global PBGM01 clinical trial program -
Passage Bio Teams with Catalent to Start CGMP Manufacturing for Lead Gene Therapy Products
07:00am, Monday, 07'th Dec 2020
- Completion of dedicated CGMP suite enhances manufacturing readiness and secures supply chain control to support lead CNS gene therapy product candidates as they advance through clinical trials to co
Passage Bio to Present at Piper Sandler 32nd Annual Healthcare Conference
04:01pm, Monday, 23'rd Nov 2020
PHILADELPHIA, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system
Through its unique collaboration agreement, Passage Bio has certain rights to technology highlighted in the University's research, which has the potential to significantly advance nascent field of gen
Passage Bio to Participate in Upcoming November Investor Conferences
07:00am, Wednesday, 11'th Nov 2020
PHILADELPHIA, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system
Passage Bio, Inc. (PASG) CEO Karl Bruce Goldsmith on Q3 2020 Results - Earnings Call Transcript
01:48pm, Tuesday, 10'th Nov 2020
Passage Bio, Inc. (PASG) CEO Karl Bruce Goldsmith on Q3 2020 Results - Earnings Call Transcript
Passage Bio Reports Third Quarter 2020 Financial Results and Recent Business Highlights
07:00am, Tuesday, 10'th Nov 2020
– Dosing for first patient in PBGM01 Phase 1/2 trial anticipated in 1Q2021; initial safety and biomarker data expected mid-year 2021 – – Phase 1/2 clinical trials for FTD-GRN and Krabbe expected
Genetic testing, educational materials and counseling offered at no charge to patients Genetic testing, educational materials and counseling offered at no charge to patients
Passage Bio to Report Third Quarter 2020 Financial Results on November 10, 2020
07:00am, Wednesday, 04'th Nov 2020
PHILADELPHIA, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system
Passage Bio's PBKR03 Receives Orphan Drug and Rare Pediatric Disease Designations from FDA for Treatment of Krabbe Disease
07:00am, Wednesday, 28'th Oct 2020
PHILADELPHIA, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system
Passage Bio: Why The Market Regards This New IPO So Highly
04:26pm, Monday, 31'st Aug 2020
Passage Bio has a well-populated development pipeline with a focused approach. Its newly listed stock has held well during this turbulent pandemic outbreak time.
U.S. IPO Week Ahead: Chinese EV's Billion-Dollar Deal Closes Out Summer In A 2-IPO Week
05:37am, Sunday, 23'rd Aug 2020
Two IPOs and two SPACs are scheduled to go public in the week ahead. Chinese EV maker Xpeng is leading summer's last wave with a billion-dollar deal.
Stocks To Watch: Spotlight On Palo Alto Networks, Best Buy And Xpeng Motors
08:12am, Saturday, 22'nd Aug 2020
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday
Passage Bio, Inc. (PASG) CEO Bruce Goldsmith on Q2 2020 Results - Earnings Call Transcript
02:17pm, Thursday, 13'th Aug 2020
Passage Bio, Inc. (NASDAQ:PASG) Q2 2020 Earnings Conference Call August 13, 2020, 08:30 AM ET Company Participants Zoe Mita - IR, Stern Investor Relations, Inc.
Passage Bio Reports Second Quarter 2020 Financial Results and Recent Business Highlights
11:00am, Thursday, 13'th Aug 2020
– Submitted IND for PBGM01 Phase 1/2 trial; currently on FDA clinical hold pending additional review of proposed ICM delivery device – – Anticipate dosing first patient in PBGM01 Phase 1/2 t
